Jefferies Upgrades Intellia Therapeutics (NTLA) to Buy; CRISPR Technology seen as Transformative

August 5, 2016 7:14 AM EDT
Get Alerts NTLA Hot Sheet
Price: $12.90 -8.96%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 28 | New: 8
Trade NTLA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies upgraded Intellia Therapeutics (NASDAQ: NTLA) from Hold to Buy with a price target of $33.00, calling CRISPR technology transformative.

Analyst Gena Wang commetned, "NTLA issued 2Q16 earnings release and ended the quarter with sufficient cash ($301M) to support operation through 2020. We continue to see CRISPR/Cas9 as a transformative gene-editing technology and the upcoming data presentation at CSL (Aug 17-20) could provide potential upside with initial preclinical proof of concept for LNP liver delivery of CRISPR/Cas9. Our PT remain unchanged but upgrade to Buy given recent stock pullback."

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $17.66 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Upgrades

Related Entities

Jefferies & Co, Earnings, Gena Wang

Add Your Comment